XENCOR INC (XNCR) Stock Price, Forecast & Analysis
NASDAQ:XNCR • US98401F1057
XNCR Key Statistics, Chart & Performance
The current stock price of XNCR is 11.54 USD. In the past month the price decreased by -9.77%. In the past year, price decreased by -26.68%.
XNCR Technical Analysis
XNCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XNCR. While XNCR seems to be doing ok healthwise, there are quite some concerns on its profitability.
XNCR Financial Highlights
Over the last trailing twelve months XNCR reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 44.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -22.19% | ||
| Debt/Equity | 0.14 |
XNCR Forecast & Estimates
20 analysts have analysed XNCR and the average price target is 29.41 USD. This implies a price increase of 154.85% is expected in the next year compared to the current price of 11.54.
For the next year, analysts expect an EPS growth of 46.57% and a revenue growth 113.06% for XNCR
XNCR Ownership
XNCR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.04 | 409.148B | ||
| AMGN | AMGEN INC | 16.57 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.41 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.08 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.65 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.86 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XNCR
Company Profile
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Info
XENCOR INC
465 N. Halstead St., Suite 200
Pasadena CALIFORNIA 91016 US
CEO: Bassil I. Dahiyat
Employees: 250
Phone: 16263055900
XENCOR INC / XNCR FAQ
Can you describe the business of XENCOR INC?
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Can you provide the latest stock price for XENCOR INC?
The current stock price of XNCR is 11.54 USD. The price decreased by -0.43% in the last trading session.
What is the dividend status of XENCOR INC?
XNCR does not pay a dividend.
What is the ChartMill rating of XENCOR INC stock?
XNCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is XNCR stock listed?
XNCR stock is listed on the Nasdaq exchange.
What is XENCOR INC worth?
XENCOR INC (XNCR) has a market capitalization of 824.07M USD. This makes XNCR a Small Cap stock.
What is the outstanding short interest for XENCOR INC?
The outstanding short interest for XENCOR INC (XNCR) is 15.5% of its float.